98%
921
2 minutes
20
Objective: To explore the difference of catgut embedding effect between acupoints and non-acupoints in patients with abdominal obesity (AO).
Methods: In this multicenter, double-blind, randomized controlled trial, all subjects were randomly assigned into the acupoint catgut embedding (ACE) group and control group (catgut embedding at non-acupoints). With a 12-week actual intervention period and a 4-week period of follow-up. Waist circumference (WC), body weight, body mass index (BMI), hip circumference (HC) and appetite were applied and assessed at baseline and after 6, 12 and 16 weeks.
Results: After the total intervention phase (12 weeks), the WC, body weight, BMI, HC and visual analogue scale scores of appetite, decreased significantly in the two groups as compared to the baseline (0.001). Meanwhile, after the 4-week follow-up, the indicators still decreased significantly in the ACE group (0.001). At 12 and 16 weeks, catgut embedding at acupoints showed significantly advantages to non-acupoints in WC and appetite (0.05). No serious adverse events were observed in ACE group and control group.
Conclusions: Catgut embedding at acupoints and non-acupoints are all effective and safe for AO. ACE can effectively treat AO as expected and deliver lasting results.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320439 | PMC |
http://dx.doi.org/10.19852/j.cnki.jtcm.20230608.002 | DOI Listing |
Medicine (Baltimore)
September 2025
The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
Background: Multiple non-pharmacological and nonsurgical interventions have demonstrated efficacy in improving abdominal obesity. However, the optimal intervention remains uncertain. This study aimed to assess the relative effectiveness and safety of these interventions in reducing waist circumference, waist-to-hip ratio, waist-to-height ratio (WHtR), body mass index (BMI), and body weight among adults with abdominal obesity.
View Article and Find Full Text PDFFront Med (Lausanne)
August 2025
Department of Anorectal, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Objective: To evaluate the efficacy and safety of acupoint embedding for FC by meta-analysis, in order to provide evidence-based medical evidence for clinical practice.
Methods: A comprehensive literature search was conducted in China National Knowledge Infrastructure, WanFang, VIP, PubMed, Web of Science and The Cochrane Library for randomised controlled trials (RCTs) on ACE for FC published from inception to November 2024. The included studies were assessed for quality using the modified Jadad scale, and statistical analysis was performed using RevMan 5.
Comb Chem High Throughput Screen
August 2025
Department of Pain Management, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Introduction: Acupoint Catgut Embedding (ACE), also known as acupuncture catgut implantation, exerts analgesic effects by inhibiting Sig-1R. This study aimed to evaluate the modulatory effect of ACE on Sig-1R and its mechanism of action in alleviating nerve pain.
Methods: We assessed behavioral changes in mechanosensitive and thermosensitive pain in rats.
Int J Gen Med
August 2025
Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150086, People's Republic of China.
Purpose: Taxane-induced peripheral neurotoxicity (TIPN) severely impacts the quality of life of patients and worsens over time with cumulative drug exposure. This study aims to evaluate the efficacy and safety of Stellate Ganglion Catgut Embedding (SGCE) therapy in treating TIPN patients, exploring a novel approach to managing TIPN.
Patients And Methods: The study was conducted from June 2023 to June 2024 at the Second Affiliated Hospital of Harbin Medical University.
BMJ Open
August 2025
Dermatology Department, China-Japan Friendship Hospital, Beijing, China
Introduction: Androgenetic alopecia (AGA), the most prevalent form of hair loss in clinical practice, affects 21.3% of the male population in China. The condition significantly impacts patients' self-perception, psychological well-being and quality of life.
View Article and Find Full Text PDF